Intellia Narrows Losses, Boosts Revenue on R&D Cuts

TL;DR

**Intellia's Q3 shows a promising financial tightening, but the cash burn is still a major concern for this high-risk biotech play.**

AI Summary

Intellia Therapeutics, Inc. (NTLA) reported a net loss of $101.3 million for the three months ended September 30, 2025, an improvement from the $135.7 million net loss in the same period of 2024. Collaboration revenue increased to $13.8 million in Q3 2025 from $9.1 million in Q3 2024. Research and development expenses decreased significantly to $94.7 million in Q3 2025 from $123.4 million in Q3 2024, contributing to a reduced operating loss of $111.5 million compared to $144.8 million year-over-year. For the nine months ended September 30, 2025, the net loss was $316.9 million, down from $390.1 million in the prior year. The company's cash, cash equivalents, and marketable securities totaled $476.5 million as of September 30, 2025, down from $601.5 million at December 31, 2024. Strategic outlook remains focused on advancing CRISPR-based therapies for in vivo and ex vivo applications, with a liquidity runway expected for at least the next twelve months.

Why It Matters

Intellia's reduced net loss and R&D spending, alongside increased collaboration revenue, signal a potential shift towards greater financial discipline and strategic focus for investors. This could improve investor confidence in NTLA's ability to manage its burn rate while advancing its CRISPR pipeline, a critical factor in the highly competitive gene-editing space. For employees and customers, continued progress in clinical development, supported by a more sustainable financial footing, could lead to more stable employment and the eventual delivery of transformative therapies. The broader market will watch if this trend allows NTLA to better compete with rivals like CRISPR Therapeutics and Editas Medicine, potentially influencing valuations across the gene-editing sector.

Risk Assessment

Risk Level: high — Intellia Therapeutics reported a net loss of $101.3 million for Q3 2025 and a net loss of $316.9 million for the nine months ended September 30, 2025. The company's cash, cash equivalents, and marketable securities decreased from $601.5 million at December 31, 2024, to $476.5 million at September 30, 2025, indicating a significant cash burn despite a reduced net loss. This high burn rate, coupled with the inherent risks of clinical-stage gene editing, places the company in a high-risk category.

Analyst Insight

Investors should closely monitor Intellia's cash burn rate and the progress of its clinical pipeline. While the reduction in net loss is positive, the substantial decrease in cash and marketable securities warrants caution. Consider this a speculative investment, contingent on significant clinical milestones and further improvements in financial efficiency.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$13.8M

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

-$101.3M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$476.5M

revenue Growth

+51.6%

Revenue Breakdown

Key Numbers

• $13.8M — Collaboration Revenue (Q3 2025) (Increased from $9.1M in Q3 2024, showing a 51.6% growth.)
• $94.7M — Research and Development Expenses (Q3 2025) (Decreased from $123.4M in Q3 2024, a 23.2% reduction.)
• $101.3M — Net Loss (Q3 2025) (Improved from $135.7M in Q3 2024, a 25.4% reduction in loss.)
• $316.9M — Net Loss (9 Months Ended Sept 30, 2025) (Improved from $390.1M in the prior year, a 18.7% reduction in loss.)
• $476.5M — Marketable Securities (Sept 30, 2025) (Decreased from $672.5M at Dec 31, 2024, indicating significant cash usage.)
• $193.4M — Cash and Cash Equivalents (Sept 30, 2025) (Increased from $189.2M at Dec 31, 2024.)
• $325.5M — Net Cash Used in Operating Activities (9 Months Ended Sept 30, 2025) (Increased from $263.7M in the prior year, indicating higher operational cash burn.)
• 115.8M — Shares Outstanding (Oct 31, 2025) (Increased from 102.0M at Dec 31, 2024, due to at-the-market offerings.)

Key Players & Entities

• Intellia Therapeutics, Inc. (company) — registrant
• CRISPR (company) — gene editing technology
• Securities and Exchange Commission (regulator) — filing authority
• FASB (regulator) — accounting standards board
• $101.3 million (dollar_amount) — net loss for Q3 2025
• $13.8 million (dollar_amount) — collaboration revenue for Q3 2025
• $94.7 million (dollar_amount) — research and development expenses for Q3 2025
• $316.9 million (dollar_amount) — net loss for nine months ended Sept 30, 2025
• $476.5 million (dollar_amount) — total marketable securities as of Sept 30, 2025
• $601.5 million (dollar_amount) — total marketable securities as of Dec 31, 2024

FAQ

Risk Factors

• Clinical Trial Delays and Regulatory Hurdles [high — regulatory]: The development of novel CRISPR-based therapies is subject to extensive clinical testing and regulatory review. Delays in clinical trials or failure to obtain regulatory approval for NTLA's lead programs, such as NTLA-2001 for transthyretin amyloidosis, could significantly impact future revenue and market position. The company has experienced delays in the past, and the evolving regulatory landscape for gene editing therapies presents ongoing challenges.
• Substantial Cash Burn and Need for Future Funding [high — financial]: Intellia reported a net loss of $101.3 million in Q3 2025 and $316.9 million for the first nine months of 2025. The company's cash, cash equivalents, and marketable securities decreased to $476.5 million as of September 30, 2025. Continued high research and development expenses, which were $94.7 million in Q3 2025, indicate a significant ongoing cash burn. The company will likely require substantial future funding to advance its pipeline.
• Dependence on Key Personnel and Technology [medium — operational]: The success of Intellia's innovative CRISPR-based therapies relies heavily on its scientific team and proprietary technology. Loss of key scientific personnel or unforeseen challenges with the CRISPR-Cas9 gene editing platform could impede research and development progress. The company's ability to scale manufacturing and ensure consistent product quality for these advanced therapies is also a critical operational factor.
• Competition in Gene Editing and Rare Disease Markets [medium — market]: The field of gene editing is highly competitive, with several other biotechnology companies developing similar technologies and therapies. Intellia faces competition from established players and emerging biotechs targeting similar indications, such as rare genetic diseases. The success of competitors' programs could impact Intellia's market share and pricing power.
• Dilution from Equity Offerings [medium — financial]: Intellia has seen its shares outstanding increase from 102.0 million at December 31, 2024, to 115.8 million as of October 31, 2025, due to at-the-market offerings. While these offerings provide necessary capital, they result in dilution for existing shareholders, potentially impacting the stock price and earnings per share.

Industry Context

The gene editing therapeutic landscape is rapidly evolving, characterized by significant scientific innovation and intense competition. Companies like Intellia are at the forefront, developing novel CRISPR-based treatments for a range of genetic diseases. Key trends include advancements in delivery mechanisms, expansion into new therapeutic areas, and strategic partnerships to accelerate development and commercialization.

Regulatory Implications

The development of gene editing therapies faces stringent regulatory scrutiny. Intellia must navigate complex clinical trial pathways and demonstrate safety and efficacy to gain approval from bodies like the FDA. Evolving guidelines for gene therapy and potential long-term effects of gene editing present ongoing regulatory challenges and require robust compliance.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for NTLA-2001 and other pipeline assets.
2. Assess the company's cash burn rate and runway in light of ongoing R&D expenses.
3. Evaluate the competitive landscape and Intellia's differentiation in the gene editing space.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $101.3M and collaboration revenue of $13.8M. Cash and equivalents stood at $476.5M.
• 2024-09-30: End of Q3 2024 — Reported net loss of $135.7M and collaboration revenue of $9.1M, providing a year-over-year comparison.
• 2025-12-31: End of Fiscal Year 2024 — Company had $601.5M in cash, cash equivalents, and marketable securities, serving as a baseline for cash burn analysis.

Glossary

CRISPR-Cas9

A gene-editing technology that allows scientists to make precise changes to DNA. It acts like molecular scissors to cut DNA at specific locations. (This is the core technology Intellia Therapeutics uses to develop its novel therapies for genetic diseases.)

In vivo gene editing

Gene editing performed directly inside the body of a patient, targeting cells within the body. (Intellia is developing in vivo therapies, such as for transthyretin amyloidosis (NTLA-2001), which is a key part of their strategy.)

Ex vivo gene editing

Gene editing performed on cells that have been removed from the body, modified, and then returned to the patient. (Intellia also has ex vivo programs, indicating a broader application of their gene editing technology.)

At-the-market (ATM) offering

A type of equity offering where a company sells shares of its stock over a period of time at prevailing market prices. (Intellia has used ATM offerings, leading to an increase in shares outstanding and potential dilution for investors.)

Transthyretin amyloidosis (ATTR)

A rare, progressive, and life-threatening disease caused by the buildup of abnormal amyloid protein deposits in organs and tissues. (NTLA-2001, one of Intellia's lead drug candidates, is targeting this disease, making it a key focus for the company.)

Year-Over-Year Comparison

Compared to the prior year, Intellia Therapeutics has demonstrated improved financial performance with a reduced net loss of $101.3 million in Q3 2025 versus $135.7 million in Q3 2024, and a 51.6% increase in collaboration revenue to $13.8 million. However, research and development expenses, while reduced year-over-year, remain substantial, contributing to a significant cash burn. The company's cash position has decreased, and shares outstanding have increased due to equity offerings, indicating ongoing funding needs and potential dilution.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma

Filing Documents

• ntla-20250930.htm (10-Q) — 2958KB
• ntla-ex31_1.htm (EX-31.1) — 15KB
• ntla-ex31_2.htm (EX-31.2) — 15KB
• ntla-ex32_1.htm (EX-32.1) — 10KB
• 0001193125-25-269680.txt ( ) — 10496KB
• ntla-20250930.xsd (EX-101.SCH) — 1273KB
• ntla-20250930_htm.xml (XML) — 1934KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for the Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures . 33

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 33

Risk Factors

Item 1A. Risk Factors 34 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 79

Other Information

Item 5. Other Information 79

Exhibits

Item 6. Exhibits 80

– FINANCI AL INFORMATION

PART I – FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 193,389 $ 189,182 Marketable securities 317,655 412,333 Accounts receivable 11,050 8,517 Prepaid expenses and other current assets 59,847 29,831 Total current assets 581,941 639,863 Marketable securities - noncurrent 158,814 260,215 Property and equipment, net 20,421 27,381 Operating lease right-of-use assets 117,883 219,292 Investments and other assets 46,216 44,264 Total assets $ 925,275 $ 1,191,015 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 13,260 $ 14,589 Accrued expenses 40,841 55,355 Current portion of operating lease liability 27,378 20,246 Current portion of deferred revenue 12,247 20,661 Total current liabilities 93,726 110,851 Deferred revenue, net of current portion 12,539 18,256 Long-term operating lease liability 70,588 189,952 Total liabilities 176,853 319,059 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, $ 0.0001 par value; 240,000,000 shares authorized at September 30, 2025 and December 31, 2024; 115,787,285 and 102,029,594 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 12 10 Additional paid-in capital 3,241,728 3,048,741 Accumulated other comprehensive income 990 605 Accumulated deficit ( 2,494,308 ) ( 2,177,400 ) Total stockholders' equity 748,422 871,956 Total liabilities and stockholders' equity $ 925,275 $ 1,191,015 See notes to condensed consolidated financial statements. 3 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Amounts in thousands

View Full Filing

View this 10-Q filing on SEC EDGAR